The DOI matches its Crossref record; 405 of the 405 references it cites were found in a registry or an index.
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Open accessAbstract
Cyclin-dependent kinases (CDK/Cyclins) form a family of heterodimeric kinases that play central roles in regulation of cell cycle progression, transcription and other major biological processes including neuronal differentiation and metabolism. Constitutive or deregulated hyperactivity of these kinases due to amplification, overexpression or mutation of cyclins or CDK, contributes to proliferation of cancer cells, and aberrant activity of these kinases has been reported in a wide variety of human cancers. These kinases therefore constitute biomarkers of proliferation and attractive pharmacological targets for development of anticancer therapeutics. The structural features of several of these kinases have been elucidated and their molecular mechanisms of regulation characterized in depth, providing clues for development of drugs and inhibitors to disrupt their function. However, like most other kinases, they constitute a challenging class of therapeutic targets due to their highly conserved structural features and ATP-binding pocket. Notwithstanding, several classes of inhibitors have been discovered from natural sources, and small molecule derivatives have been synthesized through rational, structure-guided approaches or identified in high throughput screens. The larger part of these inhibitors target ATP pockets, but a growing number of peptides targeting protein/protein interfaces are being proposed, and a small number of compounds targeting allosteric sites have been reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 401–405 of 405
Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors
Eglen, R. M., & Reisine, T. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003636820 · Cited by 20
Chin, K., Ohki, S., Tang, D., Cheng, H., Wang, J. H.-C., & Zhang, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.7120 · Cited by 15
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., Prado, M. D., Lallena, M. J., Torres, R., Ajamie, R. T., Kreklau, E. L., Wishart, G. N., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-b233 · Cited by 15
Weroha, S. J., Lingle, W. L., Hong, Y., Li, S. A., & Li, J. J. (2010) · Hormones and Cancer · doi:10.1007/s12672-009-0004-z · Cited by 15
Lo, M.-C., Ngo, R., Dai, K., Li, C., Liang, L., Lee, J., Emkey, R., Eksterowicz, J. E., Ventura, M. C., Young, S. W., et al. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.10.014 · Cited by 6
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Chiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 388
Metadata
- Authors
- Peyressatre, M., Prével, C., Pellerano, M., & Morris, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2015-01-23
- Volume
- 7
- Issue
- 1
- Pages
- 179-237
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2143238584
- Cited by
- 344
- References
- 405
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.